Crossmark

Cytogenetic and molecular risk-driven conditioning intensity in acute myeloid leukemia patients undergoing stem cell transplantation with post-transplant cyclophosphamide: a study from the acute leukemia working party of the EBMT

Crossref DOI link: https://doi.org/10.1038/s41409-025-02527-z

Published Online: 2025-02-12

Published Print: 2025-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sanz, Jaime https://orcid.org/0000-0001-6934-4619
Labopin, Myriam https://orcid.org/0000-0003-4514-4748
Versluis, Jurjen https://orcid.org/0000-0003-2372-1663
Blaise, Didier https://orcid.org/0000-0002-5684-9447
Lazzari, Lorenzo https://orcid.org/0000-0003-0844-0708
Montoro, Juan https://orcid.org/0000-0003-0024-8068
Van Gorkom, Gwendolyn

von dem Borne, Peter https://orcid.org/0000-0002-7470-7346
Sandrine, Loron

Rovira, Montserrat

Reményi, Péter

Chevallier, Patrice https://orcid.org/0000-0003-3142-5581
Kwon, Mi https://orcid.org/0000-0002-3855-7774
Eder, Matthias

Vydra, Jan https://orcid.org/0000-0002-4274-3895
Brissot, Eolia https://orcid.org/0000-0003-4471-418X
Spyridonidis, Alexandros https://orcid.org/0000-0003-3097-2532
Piemontese, Simona https://orcid.org/0000-0002-5908-0792
Mohty, Mohamad https://orcid.org/0000-0002-7264-808X
Ciceri, Fabio
License Information

Text and Data Mining valid from 2025-02-12

Version of Record valid from 2025-02-12
More Information

Article History

Received: 27 August 2024

Revised: 14 January 2025

Accepted: 31 January 2025

First Online: 12 February 2025

Competing interests

: The authors declare no competing interests.

: The scientific board of the ALWP of EBMT approved this study. All patients gave written informed consent for the use of their data. All methods were performed in accordance with the relevant guidelines and regulations.

: Not applicable for individual patient data. This is a pooled analysis.

Document is current

Any future updates will be listed below